Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

Omicron evades some but not all monoclonal antibodies: study, VUMC Reporter

Delta-Omicron recombinant escapes therapeutic antibody neutralization - ScienceDirect

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern - eBioMedicine

Omicron may sideline two leading drugs against COVID-19

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Monoclonal antibodies

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

How monoclonal antibodies work against omicron variant - ABC News

Monoclonal antibodies can't keep Omicron variant in check, 2021-12-27